65645-32-1Relevant academic research and scientific papers
COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
-
Page/Page column 64, (2010/06/19)
The invention relates to substituted 1,2-ethylenediamines of general formula (I), wherein the radicals R1-R13, A, B, L and i are as defined in the description and the claims. The invention also relates to the use thereof for treating Alzheimer's disease (AD) and similar diseases.
COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
-
Page/Page column 44, (2010/07/08)
The invention relates to substituted 1,2-ethylenediamines of general formula (I), wherein the radicals R1-R13, A, B, L and i are as defined in the description and in the claims. The invention also relates to the use thereof for treat
Chain-branched 1,3-dibenzylthioureas as vanilloid receptor 1 antagonists
Ryu, Chong Hyun,Jang, Mi Jung,Jung, Jeong Wha,Park, Ju-Hyun,Choi, Hye Young,Suh, Young-Ger,Oh, Uhtaek,Park, Hyeung-Geun,Lee, Jeewoo,Koh, Hyun-Joo,Mo, Joo-Hyun,Joo, Yung Hyup,Park, Young-Ho,Kim, Hee-Doo
, p. 1751 - 1755 (2007/10/03)
A series of chain-branched 1,3-dibenzylthiourea derivatives were synthesized, and tested their antagonist activity against vanilloid receptor 1. Chain-branching led to a significant change in the mode of action and the potency. (R)-Methyl or ethyl-branched 1,3-dibenzylthiourea derivatives showed the most potent antagonist activity up to the IC50 value of 0.05 μM which is 10-fold more potent than capsazepine.
